Neuropsychopharmacology
- Finding new and better treatments for psychiatric disorders3 years ago
- Calcitonin receptor signal: a potential target for opioid use disorder?3 years ago
- Unraveling the cell-type-specific molecular pathways of PTSD: integrating GWAS with brain genomic profiling and in vitro modeling3 years ago
- Towards personalized medicine: subtyping using functional profiles3 years ago
- Postmortem-derived iPSC models in substance use disorders research3 years ago
- A path to novel, effective treatments for schizophrenia3 years ago
- Transcranial focused ultrasound (tFUS): a promising noninvasive deep brain stimulation approach for pain3 years ago
Journal of Psychopharmacology
- Acute subjective effects in LSD- and MDMA-assisted psychotherapy6 years ago
- Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans6 years ago
- Selective activation of D1 dopamine receptors exerts antidepressant-like activity in rats6 years ago
- Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy6 years ago
- Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale6 years ago
- Antidepressant responses in direct comparisons of melancholic and non-melancholic depression6 years ago
- Neurobiological mechanisms associated with antipsychotic drug-induced dystonia6 years ago
European Neuropsychopharmacology
- Are we ready for precision medicine for Autism? And who wants it?5 years ago
- Drug development in ASD, an ISCTM-ECNP joint adventure5 years ago
- GABAA receptor agonist cinazepam and its active metabolite 3-hydroxyphenazepam act differently at the presynaptic site5 years ago
- Reinforcement learning abnormalities in the attenuated psychosis syndrome and first episode psychosis5 years ago
- Systematic comparison of duration of untreated illness versus duration of untreated psychosis in relation to psychopathology and dysfunction in the Cavan-Monaghan first episode psychosis study (CAMFEPS)5 years ago
- Comorbidities and behavioral issues5 years ago
- Sex-specific associations of basal steroid hormones and neuropeptides with Conduct Disorder and neuroendocrine mediation of environmental risk5 years ago